Mail Us

contact@liqomics.com

Call Us

(+49) 221 69 056 597

LIQOMICS
The future of minimal residual disease in cancer.

At LIQOMICS we strive to improve cancer treatment. Requiring only a blood sample, we use circulating tumor DNA (ctDNA) to understand the genetics of individual cancer, detect minimal residual disease (MRD), and monitor treatment with razor-sharp sensitivity.

Doctors Timetable

8 AM - 5 PM , Monday - Saturday

Emergency Call

Contact us on Number

Make An Appointment

Take Care Of Your Healthy Life

5 3
Dna1
About

Cutting-edge liquid biopsy technology for genotyping and disease monitoring

LIQOMICS is an academic spin-off company from Cologne, Germany. We aspire to bring our cutting-edge liquid biopsy technology for genotyping and disease monitoring to patients worldwide.

Exciting Updates for the Hematology and Oncology Community – Minimal residual disease in Hodgkin Lymphoma

We’re thrilled that next week, from October 26-28, 2024, the highly anticipated 13th International Symposium on Hodgkin Lymphoma (ISHL 13) will take place in Cologne. This world-renowned event brings together leading experts, researchers, and clinicians in the field of hematology and oncology, all united in the fight against Hodgkin Lymphoma. As a key player in this space, we at Liqomics are excited to contribute to the discussions that will shape the future of lymphoma research and treatment.

Highly sensitive minimal residual disease (MRD) detection

The Liqomics MRD test is a crucial tool for the early detection of low level MRD in cancer patients. With our proprietary workflow and bioinformatics we detect cancer with higher sensitivity than others. This can enable an earlier intervention in case of a relapse and hence an improved disease outcome for the patients.

Liqomics: Highly Sensitive Minimal Residual Disease (Mrd) Detection

Some key statistics of our assay

Sensitivity for Genotyping (SNPs / InDels) > 93%

Specificity for Genotyping (SNPs / InDels) > 99.999%

Sensitivity for MRD detection at MRD level > 10-5 > 88%

Specificity for MRD detection at MRD level > 10-5 > 99%

Limit of Detection for MRD ~ 5 x 10-6

What makes us different

Our proprietary technology allows us to be more sensitive and specific when it comes to genotyping and minimal residual disease (MRD) detection across cancers. This is crucial in situations of low disease burden.

LIQOMICS
COMPETITORS
Input Material
Only blood needed
Often tumor tissue needed
Detection Threshhold
Few DNA molecules per million (10-6)
Mostly higher (10-3-10-5)
Applicability
All cancers
Often only specific cancers
Design Principle
Universal assay for all patients with a type of cancer
Often patient-individual assay with high assay costs
Features
MRD, Genotying and additional bespoke features easily possible
often only one feature
LIQOMICS
COMPETITORS
Applicability
Platform applicable to all cancers
Often only applicable to specific cancers
Features
MRD, Genotyping, additional features possible
Often only MRD or Genotyping
Design principle
Universal assay for all patients with a particular cancer or group of cancers making assay cheaper
Often individual assay for patients needed with high assay costs
Detection threshold for MRD
Few cancer DNA molecules per million (10-6)
Mostly higher (10-3-10-5)
Input material
Only blood needed
Often tumor-informed approach, tumor tissue needed

Learn more about our assay

To Quantify Minimal Residual Disease (Mrd). Cancer Treatment Assessment

Our assay uses tumor mutations that we identify and track in blood to inform on the genetic drivers of a tumor and to quantify minimal residual disease (MRD)

Publications

Here are some publications from our early development showing applications in Hodgkin Lymphoma and CNS Lymphoma.

Heger et al

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. Blood (2024) 143 (6): 522–534.
(LINK: https://doi.org/10.1182/blood.2023022020 )

Sobesky et al

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection. Med (2021) 2 (10), 1171-1194.
(LINK: https://doi.org/10.1016/j.medj.2021.09.002 )

Heger et al

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma. Journal of Clinical Oncology (2024)
(LINK: https://doi.org/10.1200/JCO.23.01867 )

Liqomics: Minimal Residual Disease (Mrd) In Liquid Biopsy
Publications
Testimonials

What Clients Say About Us

Mklvkte
Joey Griffiths CEO, A Startup

Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua

Uufgsjh
Florrie Braun Co-Founder HCM

Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua

3Sumau
Daniel Thompson Entrepreneur

Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua

Our Blog

Lates News & Articles

Subscribe To Our Newsletter

Lorem ipsum dolor sit amet, consecte adipiscing elit, sed do eiusmod tempor incidiunt ut labore